Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue.
Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024.
The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million.
Equipment delivery supports commissioning pathway for planned U.S. rare earth magnet recycling platform; on-site operational milestone events to be announced following commissioning
Read More
Partnership expands resources to help advisory firms to strengthen valuation, enhance short- and long-term goals, and build succession strategies.
Read More
Lack of objectivity has led to a decline in legacy programing ratings while Patriot.TV (CBMJ) growth exceeds Disney (DIS), Paramount Global (PARA), Comcast (CMCSA), Newsmax (NMAX), Sinclair (SBGI), Warner Bros. Discovery (WBD), and Fox Corp. (FOX).
Read More
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments
Read MoreGelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.
Ori Gon brings substantial public company, medtech, and capital markets experience
Read MoreTargeting Q1 2026 Launch, Subject to FDA Clearance
Key Highlights:
Cartridge & Infusion Set Lots in Production: Validation production lots now being produced for launch, derisking commercial-scale production.
First Removable Tubeless Patch Pump: Pivot targets underserved "almost-pumpers" - adults with diabetes hesitant to move from multiple daily injections (MDI) due to cost and complexity - representing a significant portion of the growing ~$8 billion global insulin pump market.
Affordable, User-Friendly Design: A full 3ml removable cartridge and pump with a simple interface expands access for millions managing diabetes with MDI by providing significant clinical therapy improvement
5E Seeks to Collaborate with U.S. Magnet Producer to Solve Ferroboron Supply Gap
U.S. Supply Chains for Ferroboron are Import-Reliant with Significant Supply Chain Risk Tied to Chinese Manufacturing
Read MoreAI Nose advances through a dual-engine architecture, enabling scalable deployments
Industrial and semiconductor deployments broaden Ainos' commercial footprint
Robotics momentum accelerates data flywheel growth and commercial scale-up in 2026
Read More
New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR Initiatives and Accelerating Demand for SATUSEHAT Interoperability Operations
Read More
Formal process to evaluate ‘Stage 1' financing strategy in parallel with DFS
HIGHLIGHTS
Definitive Feasibility Study (DFS) and upgrade drilling underway for ‘Stage 1' operations at Central Gawler Mill (CGM), following dual Challenger JORC (2012) Mineral Resources upgrades to 313koz Au1
Early discussions underway with multiple credit, minerals trading and other investment groups who have approached Barton with an interest to participate in and / or finance ‘Stage 1' operations
Bedrock Advisory Partners appointed to manage credit portion of Barton's ‘Stage 1' finance process
Total net revenue of $15.2 million
Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments
$30.0 million cash balance at December 31, 2025
Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market
Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time
Read More